Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

This is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative early breast cancer with residual disease after neoadjuvant chemotherapy

Trial Details

NCT ID
NCT07400523
Phase
PHASE3
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • Ribociclib plus aromatase inhibitor
  • Aromatase inhibitor
Locations (sample)
  • Zhanjiang, Guangdong, China|21.23391,110.38749
  • Guangzhou, China|23.11667,113.25
  • Guangzhou, China|23.11667,113.25
  • Shantou, China|23.35489,116.67876

Key Eligibility Criteria

  • Willingness for study participation with written informed consent
  • Female with age at least 18 years
  • Histologically confirmed unilateral or bilateral primary invasive breast cancer
  • Residual invasive disease post-neoadjuvant either in the breast or as residual nodal invasion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →